Amezquita v. Collins

Plain English (For Everyone)

A court ruled that a patent for a method of treating a condition using a specific drug dosage was not valid. The court decided that the patent claimed a natural discovery and a standard medical procedure, not an inventive new invention. Therefore, it doesn't qualify for patent protection.

For Legal Practitioners

The Federal Circuit affirmed the PTAB's § 101 rejection of claims directed to a method of treatment based on a drug dosage correlation. The court found the claims recited a natural phenomenon and conventional diagnostic/treatment steps, lacking an inventive concept sufficient to transform the abstract idea into patent-eligible subject matter.

For Law Students

This case illustrates the application of the Alice/Mayo test, where claims directed to a natural phenomenon (drug dosage correlation) and conventional steps were found ineligible under § 101 for lacking an inventive concept. It highlights the need for claims to add significantly more than the underlying ineligible concept.

Newsroom Summary

A federal court upheld a decision denying a patent for a medical treatment method. The court found the patent claim was based on a natural discovery and routine medical practice, not an innovative invention, making it ineligible for patent protection.

Standard of Review

De novo review. The Federal Circuit reviews the Patent Trial and Appeal Board's (PTAB) determination of patent eligibility under 35 U.S.C. § 101 as a question of law, subject to de novo review.

Procedural Posture

The case reached the Federal Circuit on appeal from a final written decision by the Patent Trial and Appeal Board (PTAB) that certain claims of U.S. Patent Application No. 15/178,801 were unpatentable under 35 U.S.C. § 101.

Burden of Proof

The patent applicant bears the burden of demonstrating that their claims are patent-eligible. The standard is whether the claims recite eligible subject matter under § 101.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

Claims that merely recite a natural phenomenon and a conventional diagnostic step, without further inventive concept, are not patent-eligible under 35 U.S.C. § 101.

A method of treatment claim that is directed to a natural phenomenon and a conventional diagnostic step does not transform the claim into a patent-eligible application if it does not add significantly more to the natural phenomenon.

Remedies

Affirmed the PTAB's decision that the claims were unpatentable.

Scenario: You have discovered a specific dosage of an existing drug that is particularly effective for treating a certain disease, and you want to patent this discovery.

Your Rights: You may not be able to patent the method of treatment if the court finds it is merely a natural phenomenon (the drug's effect at that dosage) combined with conventional diagnostic or treatment steps, and lacks a sufficient inventive concept.

What To Do: Consult with a patent attorney to ensure your claims are drafted to include specific, inventive steps beyond the natural discovery and conventional methods, potentially involving a novel diagnostic tool or a unique application of the drug.

Is it legal to patent a medical treatment method based on a specific drug dosage?

Depends. While methods of treatment can be patentable, claims directed to a natural phenomenon (like a drug's effect at a specific dosage) combined with conventional diagnostic or treatment steps may be deemed ineligible under 35 U.S.C. § 101 if they lack an inventive concept.

This applies to patent law in the United States.

For Biotechnology and Pharmaceutical Companies

Companies seeking to patent new uses or dosages of existing drugs must ensure their claims go beyond merely reciting the natural correlation between the drug and its effect, and include specific, inventive steps to overcome § 101 challenges.

For Medical Researchers

Researchers discovering natural correlations or effects of treatments should be aware that patenting these discoveries as simple methods of treatment may be difficult if they do not involve a novel application or inventive concept.

Q: What is Amezquita v. Collins about?

Amezquita v. Collins is a case decided by Federal Circuit on May 5, 2025.

Q: What court decided Amezquita v. Collins?

Amezquita v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Amezquita v. Collins decided?

Amezquita v. Collins was decided on May 5, 2025.

Q: What is the citation for Amezquita v. Collins?

The citation for Amezquita v. Collins is 135 F.4th 1369. Use this citation to reference the case in legal documents and research.

Q: What was the main issue in Amezquita v. Collins?

The main issue was whether a method for treating a patient's condition using a specific drug dosage was patent-eligible under 35 U.S.C. § 101. The court found it was not.

Q: What is 35 U.S.C. § 101?

35 U.S.C. § 101 defines what subject matter is eligible for patent protection in the United States, including processes, machines, manufactures, and compositions of matter.

Q: Is Amezquita v. Collins published?

Amezquita v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Amezquita v. Collins?

The court ruled in favor of the defendant in Amezquita v. Collins. Key holdings: The court held that claims directed to a method of treating a patient by administering a specific drug dosage are not patent-eligible under 35 U.S.C. § 101 if they claim an abstract idea without sufficient inventive concept.; The court affirmed the PTAB's determination that the claims at issue were directed to an abstract idea, specifically the correlation between drug dosage and patient response, which is a natural phenomenon.; The court found that the claims did not contain additional elements sufficient to transform the abstract idea into a patent-eligible application, as the diagnostic step was conventional and did not add significantly more.; The court applied the Alice/Mayo two-step framework to assess patent eligibility under § 101.; The court rejected the patentee's argument that the claims were directed to a specific application of the abstract idea, finding that the claims were too broad and encompassed the abstract idea itself..

Q: Why is Amezquita v. Collins important?

Amezquita v. Collins has an impact score of 60/100, indicating significant legal impact. This decision further clarifies the application of the Alice/Mayo framework to methods involving medical treatments and drug dosages. It emphasizes that simply identifying a correlation or a conventional diagnostic step alongside an abstract idea is insufficient for patent eligibility under § 101, pushing innovators to demonstrate a more concrete inventive concept in their claims.

Q: What precedent does Amezquita v. Collins set?

Amezquita v. Collins established the following key holdings: (1) The court held that claims directed to a method of treating a patient by administering a specific drug dosage are not patent-eligible under 35 U.S.C. § 101 if they claim an abstract idea without sufficient inventive concept. (2) The court affirmed the PTAB's determination that the claims at issue were directed to an abstract idea, specifically the correlation between drug dosage and patient response, which is a natural phenomenon. (3) The court found that the claims did not contain additional elements sufficient to transform the abstract idea into a patent-eligible application, as the diagnostic step was conventional and did not add significantly more. (4) The court applied the Alice/Mayo two-step framework to assess patent eligibility under § 101. (5) The court rejected the patentee's argument that the claims were directed to a specific application of the abstract idea, finding that the claims were too broad and encompassed the abstract idea itself.

Q: What are the key holdings in Amezquita v. Collins?

1. The court held that claims directed to a method of treating a patient by administering a specific drug dosage are not patent-eligible under 35 U.S.C. § 101 if they claim an abstract idea without sufficient inventive concept. 2. The court affirmed the PTAB's determination that the claims at issue were directed to an abstract idea, specifically the correlation between drug dosage and patient response, which is a natural phenomenon. 3. The court found that the claims did not contain additional elements sufficient to transform the abstract idea into a patent-eligible application, as the diagnostic step was conventional and did not add significantly more. 4. The court applied the Alice/Mayo two-step framework to assess patent eligibility under § 101. 5. The court rejected the patentee's argument that the claims were directed to a specific application of the abstract idea, finding that the claims were too broad and encompassed the abstract idea itself.

Q: What cases are related to Amezquita v. Collins?

Precedent cases cited or related to Amezquita v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: Why was the patent claim found ineligible?

The court determined the claim was directed to a natural phenomenon (the correlation between drug dosage and patient response) and a conventional diagnostic step, lacking an 'inventive concept' to make it patent-eligible.

Q: What is an 'inventive concept' in patent law?

An inventive concept is an additional element or set of elements in a patent claim that transforms an otherwise ineligible idea (like a natural phenomenon or abstract idea) into a patent-eligible application.

Q: Does discovering a natural correlation between a drug and a disease make it patentable?

No, not necessarily. Discovering a natural correlation is often considered a natural phenomenon, which is an exception to patent eligibility. The claim must add something inventive beyond the discovery itself.

Q: What is the Alice/Mayo test?

The Alice/Mayo test is a two-step framework used by courts to determine if a patent claim is eligible under 35 U.S.C. § 101, by first identifying if it's directed to an ineligible concept and then looking for an inventive concept.

Q: How does Amezquita v. Collins affect me?

This decision further clarifies the application of the Alice/Mayo framework to methods involving medical treatments and drug dosages. It emphasizes that simply identifying a correlation or a conventional diagnostic step alongside an abstract idea is insufficient for patent eligibility under § 101, pushing innovators to demonstrate a more concrete inventive concept in their claims. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: Can I patent a specific dosage of an existing drug?

It depends. If the claim merely describes the natural effect of that dosage and uses conventional methods, it may be ineligible. You need to show an inventive concept beyond the natural discovery.

Q: What should I do if I discover a new medical treatment?

Consult with a patent attorney. They can help you draft claims that include specific, inventive steps beyond natural phenomena or abstract ideas to increase the likelihood of patent eligibility.

Q: How does this ruling affect pharmaceutical companies?

It reinforces that companies must demonstrate more than just a natural correlation or effect of a drug at a certain dosage to obtain patent protection for treatment methods.

Q: Are there any historical cases related to this ruling?

This ruling builds upon Supreme Court decisions like Alice Corp. v. CLS Bank International and Mayo Collaborative Services v. Prometheus Laboratories, Inc., which established the framework for analyzing patent eligibility of abstract ideas and laws of nature.

Q: What is the significance of the PTAB in this case?

The Patent Trial and Appeal Board (PTAB) made the initial decision that the patent claims were ineligible. The Federal Circuit reviewed and affirmed the PTAB's decision.

Q: What was the docket number in Amezquita v. Collins?

The docket number for Amezquita v. Collins is 23-1975. This identifier is used to track the case through the court system.

Q: Can Amezquita v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What does 'de novo review' mean in this case?

De novo review means the Federal Circuit reviewed the PTAB's decision on patent eligibility from scratch, without giving deference to the PTAB's legal conclusions.

Q: What was the procedural posture of the case?

The case came to the Federal Circuit on appeal from a final written decision by the Patent Trial and Appeal Board (PTAB) that rejected the patent claims as ineligible.